NIH-NCATS E-Newsletter: November 2020

Volume 09 │ Issue 11│ December 01, 2020

DIRECTOR’S MESSAGE
Director's Message

In his latest message, the director discusses NCATS’
role in coordinating the ACTIV-1 Immune Modulator
Phase 3 clinical trial, which is evaluating if temporarily
suppressing the COVID-19 “cytokine storm” response
can save lives. Read More

WHAT’S HAPPENING

CTSA Program Plays Key Role in Expansion of Two Rigorous Convalescent Plasma Clinical Trials

NCATS Patent Book Showcases Innovation, Collaboration and Opportunities for New Partnerships Antibiotic for Zika NINDS release
CTSA Program Hubs, Trusted Community Partners During COVID-19 Speeding Rare Disease Clinical Trials Through Gene Therapy Research

ANNOUNCEMENTS & OPPORTUNITIES
Funding Opportunity: Drug Development Collaboratory between TDB-Extramural Researchers Early Submission by Jan. 21, 2021 Save the Date: Virtual NCATS Advisory Council Meeting Watch on Jan. 14, 2021
Training Opportunity: Translational Science Interagency Fellowship Applications Due by Jan. 15, 2021 Applications Now Open for ASPIRE 2020 Challenge Apply by Feb. 28, 2021
Funding Opportunities Collaborate with NCATS Scientists

MEET NCATS STAFF
Jamie Mihoko Doyle, Ph.D. William F. Borschel, Ph.D.

Jamie Mihoko Doyle, Ph.D.

is a program director in the Division of Clinical Innovation.

William F. Borschel, Ph.D.

is a research scientist in the Therapeutic Development
Branch within NCATS’ Division of Preclinical Innovation.

Learn more about these and other staff members >

CONTACT US

National Center for Advancing Translational Sciences
National Institutes of Health
6701 Democracy Boulevard, 9th Floor
Bethesda, MD 20892

For language access assistance, contact the NCATS Public Information Officer.

To view previous newsletters, click here.

 

Share this:

View all posts